<DOC>
	<DOCNO>NCT03029689</DOCNO>
	<brief_summary>The project present first prospective , randomized evaluation effect ART structure function gut microbiome . This study provide unique opportunity understand benefit ART high intestinal penetration gut microbiome . It thus key study understand bidirectional interaction microbiome host people live HIV/AIDS .</brief_summary>
	<brief_title>Clinical Trial Evaluate Effect Raltegravir Intensification ( 1.200 mg QD ) Gut Microbiota Chronically HIV-1 Infected Subject Over Time : THE RAGTIME STUDY</brief_title>
	<detailed_description>The gut microbiome essential maturation neonatal immune system adequate development function adult immune response . HIV-1 infection child adult exerts rapid severe depletion gut-associated lymphoid tissue , damage intestinal barrier , allow translocation gut commensal bacteria systemic circulation . Bacterial translocation cause chronic inflammation immune activation , lead immune deterioration premature age HIV-1-infected subject , include metabolic disturbance , cardiovascular disease , cognitive disorder HIV-associated cancer . Persistence residual HIV-1 replication presence ART associate incomplete HIV-1 suppression gut lymphatic tissue due suboptimal tissular penetration PI/s NNRTIs . In previous work institute , observe HIV-1 infection independently associate significant reduction gut microbiome richness , , turn , inversely correlate systemic inflammation . Reduced microbial richness , example , associate intestinal inflammatory disease well metabolic syndrome , diabetes obesity correlate metabolic marker . Recovering bacterial richness might thus positive impact immune activation , chronic inflammation overall health HIV-infected individual . However , achieve goal possibly require , alongside potential bacterial supplementation , use ART high penetration gut lymphoid tissue limit much possible continue damage exert residual HIV replication GALT . Antiretroviral drug higher intestinal penetration like raltegravir may effective recover intestinal microbiome composition function lower gut penetration like darunavir NNRTIs . Thereby , raltegravir intensification could associate increase intestinal microbial richness , imply improvement intestinal overall health . Despite lack evidence regard , previous study group others would favor hypothesis . Residual HIV-1 replication plasma deter ART intensification raltegravir , , part , due high penetration raltegravir intestinal tissue . Moreover , raltegravir intensification decrease peripheral CD8 T-cell activation CD45RA ( - ) create transient CD4 T-cell redistribution , revert raltegravir withdrawal . The project present first prospective , randomized evaluation effect ART structure function gut microbiome . This study provide unique opportunity understand benefit ART high intestinal penetration gut microbiome . It thus key study understand bidirectional interaction microbiome host people live HIV/AIDS</detailed_description>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Age â‰¥18 year old 2 . Documented HIV infection 3 . Stable 3drug antiretroviral treatment include PI/r/c NNRTI least 6 month . 4 . Plasma HIV1 RNA load &lt; 50 copies/mL least 12 month . 5 . Signed Informed Consent 1 . PI/r monotherapy 2 . INSTI therapy previous 6 month 3 . Evidence previous INSTI resistance 4 . Creatine clearance &lt; 50 mL/min 5 . Child Pugh B C 6 . History active uncontrolled GI disorder diseases include : 6.1 . Major surgery GI tract , exception cholecystectomy appendectomy , previous 5 year . 6.2 . Any major bowel resection time . 6.3 . Any chronic digestive disease peptic ulcer , Crohn 's disease , ulcerative colitis , coeliac disease , confirm intolerance lactose indeterminate colitis . 6.4 . Persistent infectious gastroenteritis , colitis gastritis ; persistent chronic diarrhea unknown etiology ; Clostridium difficile infection ( recurrent ) Helicobacter pylori infection ( untreated ) 6.5 . Irritable bowel syndrome ( moderatesevere ) 6.6 . Chronic constipation 6.7 . Active proctitis 7 . Antibiotic therapy within previous 2 month 8 . In woman , pregnancy breastfeeding* . Female subject childbearing potential must pregnant , plan pregnancy breastfeeding . Sexually active woman must willing use two approve method contraception ( include condom , diaphragm , spermicide , hormonal method and/or intrauterine device ) baseline end clinical trial . Sexually active men heterosexual relationship must willing use two approve method contraception partner baseline end clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Gut microbiome</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Raltegravir intensification</keyword>
	<keyword>Bacterial richness</keyword>
</DOC>